MAPT and Alzheimer disease: To maximize clinical benefits, the interdisciplinary integration of advanced disease models, biomarker innovation (e.g., tau-PET tracers), and the precision targeting of cytoskeletal homeostasis in preclinical AD is essential—a strategy poised to disrupt tau-driven neurodegeneration at its roots.